MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of ...
Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
Medpage Today on MSN
OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence
BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...
Imagine a future where the moment you’re born, a virtual avatar is created and steadily filled with personalised information that is used to assess your cancer risk at each stage of life. When you’re ...
SurvivorNet on MSN
A True Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t
How do we know which patients truly need this difficult treatment and which patients can safely skip it? The answer has arrived, delivered at the American Society for Radiation Oncology (ASTRO) 2025 ...
Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without ...
5don MSN
New imaging solution could help improve survival for patients with recurring prostate cancer
A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...
Jan Janisch-Hanzlik, Dr. Matthew Lunning and Dr. Rana Zabad discuss new multiple sclerosis therapy during a press conference at the Buffett Cancer Center in Omaha on Tuesday, Aug. 5, 2025. Black men ...
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...
It’s among the most common cancers affecting older men. But a diagnosis today isn’t always what it seems. By David Dodge An estimated one in eight men will be diagnosed with prostate cancer in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback